KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences:

  • TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 1:10 p.m. ET in Boston, MA
  • Leerink Partners 2025 Global Healthcare Conference on Monday, March 10, 2025, at 8:00 a.m. ET in Miami, FL

Each presentation will be live webcast on the Company’s website at www.kalvista.com. After the presentations, an audio archive will be available on KalVista’s website for 30 days.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the U.S. FDA, with a PDUFA goal date of June 17, 2025. In addition, we have completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other global regulatory authorities.

For more information about KalVista, please visit www.kalvista.com or follow us on social media at @KalVista and LinkedIn.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investors: Ryan Baker Head, Investor Relations (617) 771-5001 ryan.baker@kalvista.com

Media: Molly Cameron Director, Corporate Communications (857) 356-0164 molly.cameron@kalvista.com

KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more KalVista Pharmaceuticals Charts.
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more KalVista Pharmaceuticals Charts.